reports
- Jonathan Chaplin
The broadband Open Access model
We created a model to better understand the economics of Gigapower for both AT&T and Blackrock. Please use the model and give us your thoughts. The model clarifies the value of broadband assets generally. It also clarifies why we are likely to see similar JVs from Frontier, Lumen, and others. We will adapt this model for those instances in due course.
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual Bi...
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City. H.C. Wainwright 2nd Annual BioConnect Investor ConferenceDate: Monday, May 20, 2024Time: 2:00 PM ETFormat: Fireside Chat About X4 Pharmaceu...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
RM REGIONAL MANAGEMENT CORP
RHP RYMAN HOSPITALITY PROPERTIES INC.
PENN PENN NATIONAL GAMING INC.
LTRX LANTRONIX INC.
KMPR KEMPER CORPORATION
HUBB HUBBELL INCORPORATED CLASS B
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
SABR SABRE CORP.
ALPN ALPINE SELECT AG
HTLD HEARTLAND EXPRESS INC.
MAC MACERICH COMPANY
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
WDFC WD-40 COMPANY
PK PARK HOTELS & RESORTS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
BBDC BARINGS BDC INC.
GH GUARDANT HEALTH
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
PSTV PLUS THERAPEUTICS INC
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
MEGI THE BANCORP
NPCT INC.
RXO_w MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
BYON NUVEEN CORE PLUS IMPACT FD
VSTS_w RXO INC
NBBK BEYON 3D LTD
ASGI VESTIS CORPORATION
EYPT NB BANCORP INC.
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
EYEPOINT PHARMACEUTICALS
INC.
DIEBOLD NIXDORF INCORPORATED
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 M...
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility $125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today anno...
- Jonathan Moreland
RHP RYMAN HOSPITALITY PROPERTIES INC.
HUBB HUBBELL INCORPORATED CLASS B
ECL ECOLAB INC.
CTRN CITI TRENDS INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
EFR ENERGY FUELS
HTLD HEARTLAND EXPRESS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
TDUP THREDUP INC.
TBBK THE BANCORP
VPV INC.
MEGI INVESCO PA VALUE MUNI INC TST
NPCT MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
ASGI NUVEEN CORE PLUS IMPACT FD
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
DIEBOLD NIXDORF INCORPORATED
- Jonathan Chaplin
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Pr...
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial in chronic neutropenia expected at a planned company investor event in June 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq...
- Jonathan Chaplin
Autumn for Broadband 1Q24
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Industry net adds were substantially weaker in 1Q24 with all technologies seeing slower growth (except DSL which was flat). Cable was impacted the most.
- Jonathan Moreland
SPWR SUNPOWER CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
FRAF FRANKLIN FINANCIAL SERVICES CO.
ZM ZOOM VIDEO COMMUNICATIONS
MRBK INC.
RYES MERIDIAN
LUMN PATRIOT MINEFINDERS INC.
VPV LUMEN TECHNOLOGIES INC.
MEGI INVESCO PA VALUE MUNI INC TST
IZEA MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
IZEA WORLDWIDE INC
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Ru...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards ...
- Jonathan Chaplin
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and ...
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United Sta...
German American Bancorp, Inc. (GABC) Reports First Quarter 2024 Earnin...
German American Bancorp, Inc. (GABC) Reports First Quarter 2024 Earnings JASPER, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- German American Bancorp, Inc. (Nasdaq: GABC) reported first quarter 2024 earnings of $19.0 million, or $0.64 per share, compared to earnings of $21.5 million, or $0.73 per share, for fourth quarter 2023, and earnings of $20.8 million, or $0.71 per share, for first quarter 2023. First quarter 2024 operating performance was highlighted by strong linked quarter commercial real estate and retail organic loan growth, linked quarter non-public fund deposit growth, str...
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) C...
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with approval Conference call and webcast to be hosted today at 8:30 am ET BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the im...
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.